The SPAC and its pharma-cannabis target in a filing included an investor presentation covering the revised deal terms. Read more.
Shultze & Clever Leaves File Revised Merger Plan
Related Posts
HPX Borrows $410K From Sponsor as it Works on Ambipar Deal
The business combination values Ambipar Response at an implied $581 million enterprise value and a pro forma equity value of approximately $798 million.
Laris Media Acquisition Nixes $250M IPO
Laris registered the offering with the regulator in March 2021, with plans to target companies engaged in audio technology and music streaming.
Science Strategic Acquisition Corp. Charlie Files for $125M IPO
The new SPAC plans to target companies with direct to consumer brands and services, including mobile and social entertainment.
RMG Acquisition V, VI and VII All Withdraw IPOs
Collectively, the three SPACs had intended to raise $1.725 billion.